Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Valerius

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Cancer Research|July 29, 1998
Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cellsD Würflein, M Dechant, B Stockmeyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 9, 2000
Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapyB Stockmeyer, M Dechant, M van Egmond, et al.
Blood|December 31, 1997
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapyT Valerius, B Stockmeyer, A B van Spriel, et al.
Leukemia|October 19, 2011
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicityC Kellner, D Hallack, P Glorius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 21, 1998
Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodiesI A Heijnen, L J Rijks, A Schiel, et al.
British Journal of Cancer|December 17, 2003
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancerR Repp, H H van Ojik, T Valerius, et al.
Journal of Immunological Methods|July 16, 2011
Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate developmentC Kellner, W K Bleeker, J J Lammerts van Bueren, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Cancer Research|July 29, 1998
Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cellsD Würflein, M Dechant, B Stockmeyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 9, 2000
Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapyB Stockmeyer, M Dechant, M van Egmond, et al.
Blood|December 31, 1997
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapyT Valerius, B Stockmeyer, A B van Spriel, et al.
Leukemia|October 19, 2011
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicityC Kellner, D Hallack, P Glorius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 21, 1998
Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodiesI A Heijnen, L J Rijks, A Schiel, et al.
British Journal of Cancer|December 17, 2003
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancerR Repp, H H van Ojik, T Valerius, et al.
Journal of Immunological Methods|July 16, 2011
Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate developmentC Kellner, W K Bleeker, J J Lammerts van Bueren, et al.
Pageof 7